Dannis Gilbert Van Vuurden

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3048898/publications.pdf

Version: 2024-02-01

60	3,658	218677	155660
papers	citations	26 h-index	55 g-index

63	63	63	5470
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathologica, 2012, 123, 473-484.	7.7	863
2	Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nature Medicine, 2015, 21, 555-559.	30.7	473
3	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. Journal of Clinical Oncology, 2018, 36, 1963-1972.	1.6	250
4	Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. Neuro-Oncology, 2018, 20, 123-131.	1.2	184
5	Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria. Neuro-Oncology, 2015, 17, 160-166.	1.2	124
6	In Vitro Drug Response and Efflux Transporters Associated with Drug Resistance in Pediatric High Grade Glioma and Diffuse Intrinsic Pontine Glioma. PLoS ONE, 2013, 8, e61512.	2.5	108
7	Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group. European Journal of Cancer, 2017, 73, 38-47.	2.8	101
8	PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation. Oncotarget, 2011, 2, 984-996.	1.8	85
9	EZH2-Regulated DAB2IP Is a Medulloblastoma Tumor Suppressor and a Positive Marker for Survival. Clinical Cancer Research, 2012, 18, 4048-4058.	7.0	76
10	Prevalence and Risk Factors of Early Endocrine Disorders in Childhood Brain Tumor Survivors: A Nationwide, Multicenter Study. Journal of Clinical Oncology, 2016, 34, 4362-4370.	1.6	75
11	Subventricular spread of diffuse intrinsic pontine glioma. Acta Neuropathologica, 2014, 128, 605-607.	7.7	74
12	Overview of Current Drug Delivery Methods Across the Bloodâ€“Brain Barrier for the Treatment of Primary Brain Tumors. CNS Drugs, 2020, 34, 1121-1131.	5.9	73
13	Molecular Drug Imaging: ⁸⁹Zr-Bevacizumab PET in Children with Diffuse Intrinsic Pontine Glioma. Journal of Nuclear Medicine, 2017, 58, 711-716.	5.0	69
14	WEE1 Kinase Inhibition Enhances the Radiation Response of Diffuse Intrinsic Pontine Gliomas. Molecular Cancer Therapeutics, 2013, 12, 141-150.	4.1	64
15	Human pontine glioma cells can induce murine tumors. Acta Neuropathologica, 2014, 127, 897-909.	7.7	63
16	Subgroup-specific localization of human medulloblastoma based on pre-operative MRI. Acta Neuropathologica, 2014, 127, 931-933.	7.7	53
17	Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of 89Zr-Bevacizumab PET Imaging in Brain Tumor Models. Molecular Cancer Therapeutics, 2016, 15, 2166-2174.	4.1	51
18	EphB2 activity plays a pivotal role in pediatric medulloblastoma cell adhesion and invasion. Neuro-Oncology, 2012, 14, 1125-1135.	1.2	47

#	Article	IF	Citations
19	Psychosocial profile of pediatric brain tumor survivors with neurocognitive complaints. Quality of Life Research, 2016, 25, 435-446.	3.1	44
20	Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma. Clinical Cancer Research, 2020, 26, 3319-3332.	7.0	44
21	Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease. Journal of Neuro-Oncology, 2017, 132, 255-266.	2.9	42
22	A twenty-year review of diagnosing and treating children with diffuse intrinsic pontine glioma in The Netherlands. Expert Review of Anticancer Therapy, 2015, 15, 157-164.	2.4	41
23	Attenuated AMPA Receptor Expression Allows Glioblastoma Cell Survival in Glutamate-Rich Environment. PLoS ONE, 2009, 4, e5953.	2.5	39
24	Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand?. Journal of Neuro-Oncology, 2019, 145, 177-184.	2.9	36
25	Pre-B-cell leukemia homeobox interacting protein 1 is overexpressed in astrocytoma and promotes tumor cell growth and migration. Neuro-Oncology, 2014, 16, 946-959.	1.2	31
26	MELK Inhibition in Diffuse Intrinsic Pontine Glioma. Clinical Cancer Research, 2018, 24, 5645-5657.	7.0	30
27	The international diffuse intrinsic pontine glioma registry: an infrastructure to accelerate collaborative research for an orphan disease. Journal of Neuro-Oncology, 2017, 132, 323-331.	2.9	27
28	Culture methods of diffuse intrinsic pontine glioma cells determine response to targeted therapies. Experimental Cell Research, 2017, 360, 397-403.	2.6	26
29	Palliative and end-of-life care for children with diffuse intrinsic pontine glioma: results from a London cohort study and international survey. Neuro-Oncology, 2016, 18, 582-588.	1.2	25
30	A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma. Journal of Neuro-Oncology, 2017, 135, 307-315.	2.9	25
31	Effective Drug Delivery in Diffuse Intrinsic Pontine Glioma: A Theoretical Model to Identify Potential Candidates. Frontiers in Oncology, 2017, 7, 254.	2.8	25
32	Multiregional Tumor Drug-Uptake Imaging by PET and Microvascular Morphology in End-Stage Diffuse Intrinsic Pontine Glioma. Journal of Nuclear Medicine, 2018, 59, 612-615.	5.0	24
33	Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma. Journal of Neurosurgery: Pediatrics, 2017, 19, 518-530.	1.3	23
34	Convection enhanced delivery of carmustine to the murine brainstem: A feasibility study. Journal of Neuroscience Methods, 2014, 238, 88-94.	2.5	22
35	External validation of the diffuse intrinsic pontine glioma survival prediction model: a collaborative report from the International DIPG Registry and the SIOPE DIPG Registry. Journal of Neuro-Oncology, 2017, 134, 231-240.	2.9	21
36	Deceptive morphologic and epigenetic heterogeneity in diffuse intrinsic pontine glioma. Oncotarget, 2017, 8, 60447-60452.	1.8	20

#	Article	IF	Citations
37	State of affairs in use of steroids in diffuse intrinsic pontine glioma: an international survey and a review of the literature. Journal of Neuro-Oncology, 2016, 128, 387-394.	2.9	18
38	Neurofeedback ineffective in paediatric brain tumour survivors: Results of a double-blind randomised placebo-controlled trial. European Journal of Cancer, 2016, 64, 62-73.	2.8	17
39	Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group. Lancet Oncology, The, 2018, 19, e419-e428.	10.7	16
40	A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma. Journal of Neuro-Oncology, 2021, 153, 263-271.	2.9	15
41	Timed performance weaknesses on computerized tasks in pediatric brain tumor survivors: A comparison with sibling controls. Child Neuropsychology, 2017, 23, 208-227.	1.3	11
42	Neuroblastoma and DIPG Organoid Coculture System for Personalized Assessment of Novel Anticancer Immunotherapies. Journal of Personalized Medicine, 2021, 11, 869.	2.5	11
43	High Prevalence of Weight Gain in Childhood Brain Tumor Survivors and Its Association With Hypothalamic-Pituitary Dysfunction. Journal of Clinical Oncology, 2021, 39, 1264-1273.	1.6	10
44	Therapeutic total plasma exchange in a child with neuroblastoma-related anti-Hu syndrome. Pediatric Nephrology, 2005, 20, 1655-1656.	1.7	9
45	Imaged-guided focused ultrasound in combination with various formulations of doxorubicin for the treatment of diffuse intrinsic pontine glioma. Translational Medicine Communications, 2022, 7, .	1.4	8
46	18â€‰F-FDG PET standard uptake values of the normal pons in children: establishing a reference value for diffuse intrinsic pontine glioma. EJNMMI Research, 2014, 4, 8.	2.5	4
47	Commentary on â€œHistone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypesâ€. Acta Neuropathologica, 2016, 131, 793-794.	7.7	4
48	Complementary and alternative medicine in children with diffuse intrinsic pontine gliomaâ€”A SIOPE DIPG Network and Registry study. Pediatric Blood and Cancer, 2021, 68, e29061.	1.5	4
49	BT-02 * FUNCTIONALLY-DEFINED THERAPEUTIC TARGETS IN DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2015, 17, iii3-iii3.	1.2	2
50	Highlights of Children with Cancer UKâ€™s Workshop on Drug Delivery in Paediatric Brain Tumours. Ecancermedicalscience, 2016, 10, 630.	1.1	2
51	Convection-enhanced delivery: chemosurgery in diffuse intrinsic pontine glioma. Lancet Oncology, The, 2018, 19, 1001-1003.	10.7	2
52	Transitioning to molecular diagnostics in pediatric high-grade glioma: experiences with the 2016 WHO classification of CNS tumors. Neuro-Oncology Advances, 2021, 3, vdab113.	0.7	2
53	Declining free thyroxine levels over time in irradiated childhood brain tumor survivors. Endocrine Connections, 2018, 7, 1322-1332.	1.9	2
54	A High-Throughput Image-Guided Stereotactic Neuronavigation and Focused Ultrasound System for Blood-Brain Barrier Opening in Rodents. Journal of Visualized Experiments, 2020, , .	0.3	1

#	Article	IF	Citations
55	Dynamic generation of access control policies from social policies. Procedia Computer Science, 2022, 198, 140-147.	2.0	1
56	Cytotoxicity and Radiosensitization of High Grade Glioma Cells by CI-1033, an Irreversible Pan-Erbb Inhibitor. Journal of Cancer Science & Therapy, 2013, 05, .	1.7	0
57	An 8-Year-Old Girl with Ocular Swelling. Journal of Pediatrics, 2017, 181, 324-324.e1.	1.8	0
58	DIPG-15. EFFECTIVE PRECLINICAL TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA BY MELK INHIBITION. Neuro-Oncology, 2017, 19, iv7-iv8.	1.2	0
59	PATH-04. THE BLOOD-BRAIN BARRIER IN DIFFUSE MIDLINE GLIOMA AND ITS IMPLICATIONS FOR DRUG DELIVERY. Neuro-Oncology, 2020, 22, ii164-ii164.	1.2	0
60	DIPG-24. Neurological symptom improvement after re-irradiation in patients with diffuse intrinsic pontine glioma (DIPG): A retrospective analysis of the SIOP-E-HGG/DIPG project.. Neuro-Oncology, 2022, 24, i23-i23.	1.2	0